Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
1622-62-4
Molecular formula
C16H12FN3O3
Molecular weight
313.28 g/mol
Drug class
Benzodiazepine hypnoticpositive allosteric modulator of GABAA receptors
Mechanism of action
Binds the benzodiazepine site on GABAA receptor complexes and enhances GABA-mediated chloride-channel opening, increasing neuronal inhibition and producing sedative, hypnotic, anxiolytic, muscle-relaxant and anticonvulsant effects.
Indications / reported uses
Short-term treatment of severe insomnia in countries where flunitrazepam is authorised; it is controlled or not marketed in several jurisdictions because of abuse, dependence and diversion risks
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Flunitrazepam PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Flunitrazepam Permitted Daily Exposure (PDE) report (the Flunitrazepam PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Flunitrazepam Occupational Exposure Limit (OEL) report (the Flunitrazepam OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.